Rare diseases
Investigational molecules
Locations
Study of Pembrolizumab and Lenvatinib for Patients with Advanced or Recurrent Endometrial Cancer
AustriaStudy on Pembrolizumab, Lenvatinib, and Belzutifan for Patients with Liver, Colon, Pancreatic, Bile Duct, Gallbladder, Endometrial, or Esophageal Cancer
BelgiumStudy of Favezelimab Combined with Pembrolizumab (MK-4280A) for Patients with Selected Solid Tumors
FranceStudy on Hepatocellular Carcinoma: Evaluating Livmoniplimab and Budigalimab for Patients with Advanced or Metastatic Cancer After First-Line Treatment
FranceStudy on the Safety and Effectiveness of Pembrolizumab, Vibostolimab, and Lenvatinib for Patients with PD-1 Refractory Melanoma
FranceStudy on the Effectiveness and Safety of Lenvatinib, Pembrolizumab, and Chemotherapy for Patients with Advanced or Metastatic Gastroesophageal Cancer
BelgiumStudy on Pembrolizumab and Lenvatinib for Patients with Pre-Treated Thymic Carcinoma and B3-Thymoma
FranceStudy of Pembrolizumab, Favezelimab, and Lenvatinib for Patients with Renal Cell Carcinoma
FranceStudy on the Safety and Effectiveness of Pembrolizumab, Lenvatinib, and Quavonlimab for Patients with Advanced Melanoma with Brain Metastases
FranceStudy on the Effects of Volrustomig and Drug Combination for Patients with Advanced Hepatobiliary Cancer
ItalyStudy Comparing Pembrolizumab and Lenvatinib with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments
FranceStudy on the Effectiveness and Safety of Pembrolizumab, Lenvatinib, and Chemotherapy for Patients with Metastatic Esophageal Cancer
DenmarkTell us about your condition – we search every trial in Europe and connect you with the right site.
